Shanghai, China, 15 March, 2021 – Shanghai MicroPort® EP MedTech Co., Ltd. (“MicroPort® EP”) has recently obtained registration approval from the Australia Therapeutic Goods Administration (TGA) for a selection of its medical devices and accessories, including: Columbus™ 3D EP Navigation System, Columbus™ Cardiac Electrophysiology Stimulator, OptimAblate™ Cardiac RF Generator, OptimAblate™ Irrigation Pump, and OptimAblate™ Tubing Set.
Severe arrhythmias are a major cause of sudden cardiac death. While traditional pharmacological therapies can control arrhythmias to a certain extent, the cardiac radiofrequency ablation procedure is a more effective, non-pharmacological therapy in treating arrhythmias. In radiofrequency ablation procedures, the approved OptimAblate™ Cardiac RF Generator delivers high-frequency energy to block or destroy abnormal pathways to achieve a normal sinus rhythm. The OptimAblate™ Irrigation Pump, which supplies a constant flow of saline water to cool the head of the ablation catheter, ensures greater results when used in conjunction with the Cardiac RF Generator.
For surgeons desiring added safety and efficacy in their procedures, the Columbus™ 3D EP Navigation System captures and analyzes the electrophysiological activity of the heart while displaying a real-time 3D image of the heart. The Columbus™ 3D EP Navigation is both a convenient and affordable option for surgeons and patients with arrhythmias.
The TGA previously approved proprietary catheters and other consumables of MicroPort® EP for use in June last year. The successful approval of equipment and accessories further enriches and complements the product portfolio of MicroPort® EP in the Australian market, paving the way for the company to explore the Oceania market with confidence.
The future of MicroPort® EP will involve continued investments in research, development, and product innovation to provide an integrated solution that combines active and passive approaches, while bringing together equipment and devices for the benefit of patients and doctors.
About MicroPort® EP
Shanghai MicroPort EP MedTech Co., Ltd, a subsidiary of MicroPort Scientific Corporation (MicroPort®, stock code: 00853.HK), was established in the Shanghai International Medical Zone on August 31, 2010. Its concentration is on the development, manufacture, and marketing of minimally invasive medical devices for the treatment of electrophysiological diseases, including cardiac ablation catheters, diagnostic catheters, 3D navigation systems, amongst others.